The Center for Psychedelic Therapy & Research is led by Professor Janis Phelps, PhD. Dr. Phelps received her doctorate in clinical psychology from the University of Connecticut. She has been a professor at the California Institute of Integral Studies for the past 21 years. She is the former dean of the School of Consciousness and Transformation at CIIS. She is now the Director of the CIIS Center for Psychedelic Therapies and Research. As the Center's founder, she developed the first academically accredited, professional certificate training program for legal psychedelic-assisted therapy and research. The Center also provides harm reduction workshops, webinars on psychedelic research and public educational programs. A licensed clinical psychologist and LMFT, she has held faculty positions in the East-West Psychology and Clinical Psychology doctoral programs. Her theoretical orientations include transpersonal and wellness therapy models; Buddhism and Eastern disciplines; and phenomenology/existential philosophies. Her research and scholarly writing has focused on psychedelic therapy, entheogens, and mind-body wellness. Dr. Phelps teaches graduate courses in quantitative and qualitative research methods, mindfulness, Buddhism and psychotherapy, spiritual counseling, and principles of healing. Janis serves on the board of the Holos Institute and maintains a private practice.


Anthony Bossis

Anthony P. Bossis, Ph.D. is a clinical psychologist and clinical assistant professor of psychiatry at NYU School of Medicine conducting FDA-approved clinical research with the psychedelic compound psilocybin since 2009. He was director of palliative care research and co-principal investigator on the landmark 2016 clinical trial and publication demonstrating a significant reduction in psychosocial distress from a single psilocybin session in persons with cancer. He is study director and lead session guide on the FDA-approved clinical trial evaluating psilocybin-generated mystical experience upon religious leaders. Dr. Bossis is a training supervisor of psychotherapy at NYU-Bellevue Hospital Center and co-founder of the Bellevue Hospital Palliative Care Service. Dr. Bossis is on the faculty of The Center for Psychedelic Therapies and Research at the California Institute of Integral Studies in San Francisco, CA., and at the Art of Dying Institute in NYC.  He is on the editorial board of the Journal of Humanistic Psychology and a guest editor (with Charles Grob, M.D.) for the journal’s Special Series on Psychedelics. He has a long-standing interest in comparative religion and mystical experience and on the interface of psychology and spirituality.  He maintains a private psychotherapy and consulting practice in NYC.


Susana Bustos, Ph.D. (CIIS, 2008), M.A in Clinical Psychology and in Music Therapy from Chilean universities, is adjunct faculty at the California Institute of Integral Studies and other schools in the Bay Area and abroad. Susana also conducts independent research on entheogenic shamanic traditions of the Americas and holds a private practice in Berkeley, CA. Her teaching, research, and clinical work focus mainly on the healing potential of non-ordinary states of consciousness, their integration into ordinary life, and on the quest for adequately bridging Amerindian cosmologies and practices into the West. Susana has written articles and book contributions on the interphase of shamanic song and healing and on entheogenic integration, and she lectures internationally on these topics. She directed the Spiritual Emergence Network in the US between 2016 and 2020.


Blu Cohen

Blu Cohen, PsyD, earned her clinical psychology degree from CIIS. In 2010, she received training from the Mithoefers in MDMA-assisted psychotherapy for treatment-resistant PTSD. Since that time, she has been an adherence rater and trainer for the Multidisciplinary Association of Psychedelic Studies, viewing approximately 200 hours of MDMA-assisted therapy tapes. Dr. Cohen wrote her dissertation on creating a training manual and measure to capture the efficacious components of the MDMA-assisted psychotherapy model for Phase 3 studies. She is interested in the intersection of person-centered, feminist, and social justice approaches to MDMA-assisted psychotherapy as well as research and program development. Dr. Cohen currently sees individual clients and groups in private practice in San Francisco.


 

Karen CooperKaren Cooper, RN, BSN, MA, has been a Sub-investigator in Therapy Pair and Project Manager at the MAPS Fort Collins site since 2016. She was Lead Guide and Clinical Research Nurse for the University of Wisconsin’s Psilocybin Pharmacokinetic Study and served as the study trainer with the Usona Institute in Madison, WI from 2013-2016. She enjoys serving as mentor, guest faculty, and in other roles for the Center for Psychedelic Therapies and Research program at California Institute of Integral Studies and helped to launch their inaugural program. Karen’s Master’s degree in Holistic Health Education at John F. Kennedy University included a focus on transpersonal and somatic psychology. She is a Licensed Bodyworker and Massage Therapist and certified yoga teacher, with current practices of meditation and Tai Chi. She offers consultation, mentoring, and coaching to those curious about guiding in the research setting or finding meaning from psychedelic and alternate reality experiences. An eclectic nursing background from prenatal and neonates to end-of-life hospice has supported her love for teaching, science, consciousness, psychology, psychedelics, and spirituality. Her outside interests include gardening, fiber arts, and exploring the natural beauty and outdoor activities near her home in Northern Colorado with husband Dan Muller.


Mary Cosimano, LMSW, is currently with the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. She is the Director of Clinical Services for the Center for Psychedelic and Consciousness Research and has served as study guide and research coordinator for the psilocybin studies for 20 years. During that time she has been a session guide, involved with all the psilocybin studies and has conducted over 450 study sessions. She has trained post doctorate fellows, research assistants and interns as assistant guides. She has administered the psychological evaluations for psilocybin studies as well as other studies in the Behavioral Biology Research Unit. In addition to her work with the psilocybin studies, she has been involved in the Salvia Divinorum, Dextromethorphan, and Club Drug studies conducted at Johns Hopkins. She taught individual and group meditation to breast cancer patients in a Johns Hopkins research study, and taught at California Institute to Integral Studies (CIIS) for their Psychedelic-Assisted Therapies and Research program. In 2003 she started and has maintained a meditation group for employees in her department. She also has 15 years of experience with direct patient care as a hospice volunteer.


Nicholas V. Cozzi, Ph.D. is a scientist and educator at the University of Wisconsin-Madison School of Medicine and Public Health. He holds a Ph.D. in Pharmacology and a B.S. in Pharmacology and Toxicology, both from the UW-Madison School of Pharmacy. His background and training is in pharmacology, chemistry, toxicology, and neuroscience. Dr. Cozzi has more than 80 publications and is internationally recognized for his work in these areas. As an educator, Dr. Cozzi teaches pharmacology at the UW-Madison and he is a frequent guest lecturer at other academic institutions around the United States. Dr. Cozzi's research involves the design, chemical synthesis, and pharmacological testing of substances with central nervous system activity, especially those with psychedelic, antidepressant, or psychostimulant effects. He is interested in how these agents act in the brain to improve mood, enhance cognition, and increase awareness, and in their clinical value in treating addiction, anxiety, depression, post-traumatic fear, and other mental health ailments.  Dr. Cozzi has received several teaching and research awards, including a Distinguished Basic Science Teaching Award from the UW-Madison and a prestigious NARSAD Award from the Brain and Behavior Research Foundation for his work involving the serotonin uptake transporter. His research has also been supported by grants from the National Institutes of Health, the UW-Madison, and the Usona Institute. Outside the University, Dr. Cozzi serves as a scientific consultant for legal, pharmaceutical industry, and government clients.


Rick Doblin, PhD, is founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college.


Frank Echenhofer, PhD , is a licensed psychologist and a professor of Clinical Psychology at CIIS. Dr. Echenhofer conducted the first EEG meditation research study with the Dalai Lama's guidance at his monastery in India. Currently, he is the chair of CIIS's Kranzke Scholarship faculty committee that awards $5,000 scholarships to students doing psychedelic research and has chaired eight CIIS dissertations exploring different dimensions of psychedelic experience. Since 2000, he has conducted research in Peru and Brazil exploring the different ways that ayahuasca facilitates healing, creativity, and spiritual development. This research has found indications that different kinds of EEG changes after ayahuasca ingestion often correspond to different kinds of ayahuasca experiences. His current ayahuasca research explores in more detail how EEG, personality, gender, and cultural context may be related to different arcs of transformation.


Amy Emerson, BS , earned her bachelor's degree in genetics and cell biology from Washington State University in 1992. Prior to her work at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MPBC) she worked in clinical development and research beginning in 1993. Amy's previous experience is in the fields of immunology (Applied Immune Sciences), oncology (RPR), and vaccine development (Chiron and Novartis). Amy worked with MAPS as a volunteer starting in 2003 facilitating the development of the MDMA clinical program. In 2009, she began managing the Clinical Research group at MAPS. She is currently the Executive Director and Director of Clinical Research of MPBC.


George Goldsmith, MA , holds a bachelor's degree in cognitive psychology from the University of Rochester, and a master's degree in clinical psychology from the University of Connecticut. He has founded several technology companies - including The Human Interface Group, TomorrowLab, and Tapestry Networks - and served as a senior advisor to McKinsey & Company before founding COMPASS, a multi-tiered medical research foundation. COMPASS leads mental health policy dialogues; funds new treatment research protocols, including research on the clinical applications of empathogens and entheogens; and forms strategic partnerships to bring research findings into clinical, regulatory, and legislative settings.


George Greer, MD , is Medical Director and co-founder of the Heffter Research Institute. From 1980 to 1985, he conducted over 100 therapeutic sessions with MDMA for 80 individuals with his psychiatric nurse wife, Requa Tolbert. He is a Distinguished Life Fellow of the American Psychiatric Association and Past President of the Psychiatric Medical Association of New Mexico. He is also a co-investigator for the MAPS MDMA-PTSD therapist training studies.


Charles Grob, MD, is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center. His longstanding interest in the history of psychiatric research with hallucinogens has generated an impressive history of conference presentations and publications in leading medical and psychiatric journals. Dr. Grob received the first FDA approval to carry out human research with 3,4- methylenedioxymethamphetamine (MDMA) in the early 1990s. He has collaborated with Drs. Dennis McKenna and Jace Callaway on the Hoasca Project: research that explored the biochemical, physiological, and psychological impacts of long-term ayahuasca use in Brazil. From 2004 to 2008, Dr. Grob conducted an FDA-approved study examining the effects of psilocybin in advanced-stage cancer patients with severe anxiety. Results from this trial were published in the Archives of General Psychiatry in 2011. Dr. Grob, along with his colleague Dr. Alicia Danforth, recently concluded a pilot study of an MDMA treatment model for autistic adults with social anxiety. He is a founding board member of the Heffter Research Institute. Dr. Grob is the editor of Hallucinogens: A Reader, and the co-editor with Dr. Roger Walsh of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics and is working as Editor on a new book on contemporary views of psychedelic research. 




Stanislav Grof, MD , is a psychiatrist with more than 50 years of experience in researching non-ordinary states of consciousness induced by psychedelic substances and various non-pharmacological methods. He is professor emeritus at CIIS, conducts professional training programs in Holotropic Breathwork and transpersonal psychology, and gives lectures and seminars worldwide. He is one of the founders and chief theoreticians of transpersonal psychology and the founding president of the International Transpersonal Association. Dr. Grof has received the prestigious Vision 97 award from the Dagmar and Václav Havel Foundation in Prague and the Thomas R. Verny Award for his pivotal contributions to pre- and perinatal psychology. He has published more than 150 papers in professional journals and the books Realms of the Human Unconscious, Beyond the Brain, LSD Psychotherapy, The Cosmic Game, Psychology of the Future, When the Impossible Happens, The Ultimate Journey, Healing Our Deepest Wounds, Spiritual Emergency, The Stormy Search for the Self, and Holotropic Breathwork (the last three with Christina Grof).


Jeffrey Guss​, MD, is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Therapist Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer-related existential distress. He is currently a study therapist in a trial of psilocybin-assisted therapy for alcoholism and the MAPS MDMA for PTSD study, and co-wrote the therapy manual for Yale’s depression and psilocybin study. Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in ​Studies in Gender and Sexuality​ and ​Psychoanalysis, Culture, and Society​. He is an instructor and mentor for the Center for Psychedelic Therapies & Research certificate program and maintains a full-time private practice.


Diane Haug, M.A., LPCC is a licensed therapist and senior member of the Grof Transpersonal Training staff.  Her background includes a decade of working with adults and children dealing with life-threatening and terminal illness. Since completing the Grof’s first three-year training program in the 1980’s, Diane has been involved with the international Holotropic Breathwork community offering training events in South America, China, Russia, Ukraine, Spain, Czech Republic, Scandinavia, Slovenia and Mexico. She has developed and co-taught GTT training modules including Shamanism: An Exploration of Traditional Wisdom; The Art of Integration; Living with Dying; The World Within: Jung’s Red Book; and The Psychedelic Experience: Promises and Perils. Diane is an adjunct faculty member of the CIIS Center for Psychedelic-Assisted Therapies and Research (San Francisco, CA), Southwestern College (Santa Fe, New Mexico) and the Academy for the Love of Learning (Santa Fe, New Mexico). She also served on the staff for the MAPS MDMA-Assisted PTSD Therapy Training Programs in March / April 2017. Diane, who lives and maintains a small private practice outside of Santa Fe, New Mexico, is currently working with Stan and Brigitte Grof on the creation of Grof Legacy Training US – with plans to launch in 2021.


Robert Jesse is convenor of the Council on Spiritual Practices (CSP). Through CSP, he was instrumental in forming the psilocybin research team at Johns Hopkins University. He is a co-author of its first paper, "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance" (2006) and he is one of the team's co-investigators. Bob now serves on the board of Usona Institute and is an advisor to CIIS. In 2005, he led the writing of an amicus brief for the U.S. Supreme Court in a key religious liberty case that was decided 8-0, favoring the U.S. branch of the Brazilian church, the União do Vegetal. Prior to CSP, Bob worked as a consultant in information technology for AT&T Bell Labs and others, then in several capacities for Oracle Corporation, lastly as a vice president of business development. His university training is in computer science and electrical engineering.


Maria ManginiMariavittoria Mangini, PhD, FNP has been a family nurse midwife since 1985. She has written extensively on the impact of psychedelic experiences in shaping the lives of her contemporaries, and has worked closely with many of the most distinguished investigators in this field. She completed her doctorate in Community Health Nursing at UCSF, where her research centered on drug use and drug policy. She is an Emerita professor of nursing at Holy Names University in Oakland, where she was the director of the MSN/FNP program for 20 years. Her current project is the development of a Thanatology program for the study of death and dying.


Gabor Maté, MD , recently retired from active medical practice. He was a family physician for two decades and for seven years he served as medical coordinator of the palliative care unit at Vancouver Hospital. For twelve years, he worked in Vancouver's Downtown Eastside with patients challenged by hardcore addiction, mental illness, HIV, and related conditions. For two years, he was the onsite physician at Vancouver's unique Supervised Injection Site, North America's only such facility. He is internationally known for his work on mind/body unity in health and illness, on attention deficit disorder and other childhood developmental issues, and his breakthrough analysis of addiction as a psychophysiological response to childhood trauma and emotional loss. He is the author of four bestselling books published in twenty languages on five continents, including When The Body Says No: Exploring the Stress-Disease Connection and the award winning In the Realm of Hungry Ghosts: Close Encounters With Addiction. Gabor is the recipient of an Outstanding Alumnus Award from Simon Fraser University and an Honorary Degree of Law from the University of Northern British Columbia, among other awards. He frequently addresses professional and lay audiences in North America on childhood development and parenting, physical and mental health and wellness, and addiction. He is an adjunct professor in the criminology department at Simon Fraser University. His next book, Toxic Culture: Trauma, Illness, and Healing in a World of Materialism, will be published in 2016.


Dennis McKenna, PhD , is interested professionally and personally in the interdisciplinary study of ethnopharmacology and plant hallucinogens. He received his doctorate in 1984 from the University of British Columbia, where his doctoral research focused on ethnopharmacological investigations of the botany, chemistry, and pharmacology of ayahuasca and oo-koo-hé, two orally-active tryptamine-based hallucinogens used by indigenous peoples in the Northwest Amazon. Dr. McKenna received post-doctoral research fellowships in the Laboratory of Clinical Pharmacology, National Institute of Mental Health, and in the Department of Neurology, Stanford University School of Medicine. He joined Shaman Pharmaceuticals as Director of Ethnopharmacology in 1990, and relocated to Minnesota in 1993 to join the Aveda Corporation as Senior Research Pharmacognosist. He joined the faculty of the Center for Spirituality and Healing at the University of Minnesota in 2001. He is a founding board member of the Heffter Research Institute and serves on the advisory board of non-profit organizations in the fields of ethnobotany and botanical medicines. He was a key organizer and participant in the Hoasca Project, an international biomedical study of ayahuasca used by indigenous people and syncretic religious groups in Brasil.  He recently completed a project funded by the Stanley Medical Research Institute, to investigate Amazonian ethnomedicines for the treatment of schizophrenia and cognitive deficits.  At the Heffter Research Institute, he continues his focus on the therapeutic uses of psychoactive medicines derived from nature and used in indigenous ethnomedical practices. 


Natalie Metz, ND , is a licensed Naturopathic Doctor, herbalist, and core faculty member in the Integrative Health Studies department at CIIS. She has a private practice in Oakland and Santa Fe where she assists patients in their wellness with the support of plant medicine, diet and lifestyle counseling, and the integration of beyond-ordinary life experiences. She is a lifelong student of dance, a lover of art, travel, and all things purple, and enjoys sharing her passion for life with the world. Please visitwww.drnataliemetz.com. 


Annie Mithoefer, BSN, is a registered nurse living in Asheville, NC. She has many years of experience treating people with PTSD in a private practice with her husband Michael and leading Holotropic Breathwork group workshops. She has worked as co-therapist in MAPS Clinical Trials. She and her husband, Michael Mithoefer, completed the first MAPS-sponsored Phase II clinical trial testing MDMA-assisted psychotherapy for crime-related PTSD, a subsequent study with military veterans, firefighters and police officers, and a pilot study treating couples with MDMA combined with Cognitive Behavioral Conjoint Therapy for PTSD.  She is now focusing on offering MDMA therapist trainings, and on supervising therapists in ongoing Phase 3 Clinical trials. She is a Grof certified Holotropic Breathwork Practitioner and is trained in Hakomi Therapy.

Michael Mithoefer, MD,is a psychiatrist living in Asheville, NC, who, for 25 years, has specialized in experiential therapies for posttraumatic stress disorder (PTSD), and is now Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation, where he is a member of the Executive Team. He and his wife, Annie, completed the first MAPS-sponsored Phase II clinical trial testing MDMA-assisted psychotherapy for crime-related PTSD, a subsequent study with military veterans, firefighters and police officers, and a pilot study treating couples with MDMA combined with Cognitive Behavioral Conjoint Therapy for PTSD.  He has been Medical Monitor for a series of six Phase 2 trials in the US, Canada, Switzerland and Israel, which produced data that led to breakthrough therapy designation by the FDA. Since 2012, he and Annie have conducted training for research therapists and are now supervising therapists in ongoing. MAPS Phase 3 clinical trials. He received his MD degree from the Medical University of South Carolina (MUSC) and completed residency trainings in Internal Medicine at the University of Virginia and Psychiatry at MUSC. He is a certified Grof Holotropic Breathwork facilitator and is trained in Internal Family Systems Therapy and EMDR. He has been board certified in Psychiatry, Emergency Medicine and Internal Medicine. He is a Fellow of the American Psychiatric Association and Affiliate Assistant Professor at MUSC.


Lia Mix, MS, MFT , holds a master's degree in counseling with a concentration in multicultural populations and is an adjunct faculty member at CIIS. Ms. Mix has worked in multiple behavioral health settings: foster care services, dual-diagnosis outpatient care, workplace crisis response, and corporate consulting. She helped create industry-leading counseling and case management programs and has supported insurance benefit administration and design for newly adopted behavioral health treatments. Ms. Mix has provided consultation for key decision makers within a wide range of corporate, nonprofit, and governmental organizations and brokerage firms.  Her current focus is autism spectrum disorders.


David Presti, PhD , is a professor of neurobiology at the University of California, Berkeley, where he has taught for 30 years. He also worked for more than a decade in the clinical treatment of addiction and post-traumatic stress at the Veterans Administration Medical Center in San Francisco, and since 2004 has been teaching and dialoguing about neuroscience with Tibetan Buddhist monastics in India, Bhutan, and Nepal. He has been involved in shifting policy related to research and psychotherapy with psychedelics for 30 years. He has doctorates in biology from Caltech and in clinical psychology from the University of Oregon.


David E. Nichols, PhD, is Adjunct Professor of Chemical Biology and Medicinal Chemistry at the Eshelman School of Pharmacy at UNC, Chapel Hill. Previously he held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy. He also was Adjunct Professor of Pharmacology and Toxicology at the Indiana University School of Medicine. He received his B.S. in chemistry from the University of Cincinnati in 1969, and a PhD in Medicinal Chemistry from the University of Iowa in 1973, followed by postdoctoral work in pharmacology, also at Iowa. He joined Purdue as an Assistant Professor in 1974 where he remained until his retirement in June 2012. He has published more than 300 scientific articles, is recognized as a leading authority on psychedelics, and is the founding president of the Heffter Research Institute.


William Richards, STM, PhD, is a psychologist at the “Center for Psychedelic and Consciousness Research” at the Johns Hopkins University School of Medicine, where he and his colleagues have pursued research with psilocybin for the past two decades, a clinician at the Aquilino Cancer Center in Rockville MD and a clinician in private practice in Baltimore. His graduate training in clinical psychology and the psychology of religion included studies at Yale University, the University of Göttingen, Andover-Newton Theological School, Brandeis University, and Catholic University. After encountering psilocybin research in Germany in 1963, he contributed to psychotherapy research with LSD, DPT, MDA, and psilocybin at the Maryland Psychiatric Research Center from 1967 to 1977. Columbia University Press published his seminal book, Sacred Knowledge: Psychedelics and Religious Experiences, in 2015.


Jan Edl Stein , MFT is a licensed psychotherapist. Jan is also the director of Holos Institute, (www.holosinstitute.net) an educational and counseling center grounded in principles of ecopsychology where she has developed a certificate program in ecopsychology and curates an annual ecopsychology conference. Jan leads workshops and retreats that interweave meditation, active imagining, and earth-based contemplations.  She has taught/presented at Sonoma State University, The Bioneers Conference, Esalen Institute, the Institute of Noetic Sciences, and numerous private venues. For over 33 years she has maintained a private practice which includes consultation, individual and couples psychotherapy. Her depth psychology approach utilizes active imagination, liminal state explorations, ecotherapy, EMDR, Brainspotting, and somatic focusing as appropriate.  All of her work draws upon a lifelong study of spiritual traditions and healing practices of earth-based cultures and a deep love of the natural world.  More information at www.janedl.com.


Monnica WilliamsMonnica Williams, PhD, is a board-certified, licensed clinical psychologist, specializing in cognitive-behavioral therapies. She is an Associate Professor in the School of Psychology at the University of Ottawa, Canada Research Chair in Mental Health Disparities, and Director of the Laboratory for Culture and Mental Health Disparities. She is also the Clinical Director of the Behavioral Wellness Clinic, LLC in Tolland, Connecticut, and she has founded clinics in Kentucky, Virginia, and Pennsylvania. Dr. Williams has published over 100 scientific articles on mental health and culture. Her current work includes unacceptable thoughts in OCD, the impact of OCD on intimate relationships, improving cultural competence in the delivery of mental health care services, assessment of race-based trauma, and interventions to reduce racial bias. She previously served as principal investigator on a Phase 3 multisite trial for MDMA-assisted psychotherapy for PTSD, at the University of Connecticut Health Center. She also gives trainings nationally for clinical psychology programs, scientific conferences, and community organizations.


Berra Yazar-Klosinski, PhD , earned her doctorate in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz. She utilizes her scientific training and experience in for-profit pharmaceutical research to support the work of the Multidisciplinary Association of Psychedelic Studies (MAPS) to develop, design, and implement clinical psychedelic research in the U.S and beyond. She earned her BS in Biological Science from Stanford University, with an emphasis on the neurobiology of drugs. Prior to entering graduate school, Ms. Yazar-Klosinski worked as a research associate with Geron Corporation screening for drugs that activate telomerase, and with Millennium Pharmaceuticals on Phase 1 clinical trials in patients with acute myeloid leukemia. She joined MAPS in 2009 to work with an organization where profit would not dictate the agenda of scientific research. Since then, she has been actively involved in the ongoing Phase 2 clinical development of MDMA-assisted psychotherapy with an eye towards Phase 3 clinical trials.


 

Need to Contact Us?

CIIS Center for Psychedelic Therapies and Research
1453 Mission Street
San Francisco, CA 94103

Dr. Cathy Coleman
CPTR Admissions Manager | Certificate Manager
Email: ccoleman@ciis.edu
Phone: (415) 575-6261

Leslie Carson, MS, LPCC
Admission Project Assistant, and Certificate in Psychedelic-Assisted Therapies and Research Graduate 2017
Email: admincptr@ciis.edu
Phone: (415) 575-6243

We are an academic program, and we are not able to provide therapist referrals at this time.

Subscribe to the Center Newsletter

Stay Connected to CIIS